[go: up one dir, main page]

ES2084338T3 - Anticuerpos recombinantes especificos para el tnf alfa. - Google Patents

Anticuerpos recombinantes especificos para el tnf alfa.

Info

Publication number
ES2084338T3
ES2084338T3 ES92901287T ES92901287T ES2084338T3 ES 2084338 T3 ES2084338 T3 ES 2084338T3 ES 92901287 T ES92901287 T ES 92901287T ES 92901287 T ES92901287 T ES 92901287T ES 2084338 T3 ES2084338 T3 ES 2084338T3
Authority
ES
Spain
Prior art keywords
humanized
antibody molecules
diseases
human
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901287T
Other languages
English (en)
Inventor
John Robert Adair
Diljeet Singh Athwal
John Spencer Emtage
Mark William Bodmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1990/002017 external-priority patent/WO1991009967A1/en
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ES2084338T3 publication Critical patent/ES2084338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROVEEN MOLECULAS DE ANTICUERPO RECOMBINANTES, EN PARTICULAR HUMANIZADAS, POR EJEMPLO QUIMERICA HUMANIZADA Y HUMANIZADAS POR CDR-INJERTO, QUE TIENEN ESPECIFICIDAD PARA EL TNFALFA HUMANO PARA USO EN DIAGNOSIS Y TERAPIA. EN PARTICULAR LAS MOLECULAS DE ANTICUERPO TIENEN LUGARES DE ENLACE ANTIGENO DERIVADOS DE ANTICUERPOS MONOCLONALES DE MURINA CB0006, CB0010, HTNF3 O 101,4. LOS ANTICUERPOS ANTI HTNFALFA IDONEOS HUMANIZADOS POR CDR-INJERTO COMPRENDEN DOMINIOS VARIABLES QUE COMPRENDEN UN CUADRO ACEPTEDOR HUMANO Y REGIONES DE ENLACE ANTIGENO DE DONANTE Y DONDE LOS CUADROS COMPRENDEN RESIDUOS DEL DONANTE EN POSICIONES ESPECIFICAS. LAS MOLECULAS DE ANTICUERPO SE PUEDEN UTILIZAR EN EL TRATAMIENTO TERAPEUTICO DE PACIENTE HUMANOS QUE SUFRAN O ESTEN EN RIESGO DE ENFERMEDADES ASOCIADAS CON NIVELES ELEVADOS INDESEABLES DE TNF, EN PARTICULAR PARA EL TRATAMIENTO DE ENFERMEDADES INMUNOREGULATORIAS E INFLAMATORIAS O DE CHOQUE SEPTICO, ENDOTOXICO O CARDIOVASCULAR.
ES92901287T 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para el tnf alfa. Expired - Lifetime ES2084338T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB1990/002017 WO1991009967A1 (en) 1989-12-21 1990-12-21 Humanised antibodies
GB919109645A GB9109645D0 (en) 1991-05-03 1991-05-03 Recombinant antibodies

Publications (1)

Publication Number Publication Date
ES2084338T3 true ES2084338T3 (es) 1996-05-01

Family

ID=10694434

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94201456T Expired - Lifetime ES2190434T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para tnf-alfa.
ES92901287T Expired - Lifetime ES2084338T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para el tnf alfa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94201456T Expired - Lifetime ES2190434T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para tnf-alfa.

Country Status (21)

Country Link
US (1) US20030199679A1 (es)
EP (3) EP0927758A3 (es)
JP (3) JP3145401B2 (es)
KR (1) KR100253426B1 (es)
AT (2) ATE228853T1 (es)
AU (2) AU657937B2 (es)
BR (1) BR9106232A (es)
CA (3) CA2329482C (es)
DE (4) DE69133167T2 (es)
DK (2) DK0626389T3 (es)
ES (2) ES2190434T3 (es)
FI (1) FI109800B (es)
GB (2) GB9109645D0 (es)
GR (1) GR3019066T3 (es)
HU (2) HUT62661A (es)
NL (1) NL9120013A (es)
NO (2) NO923231L (es)
NZ (2) NZ260226A (es)
OA (1) OA09666A (es)
PT (1) PT99934B (es)
WO (1) WO1992011383A1 (es)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
WO1991002078A1 (en) 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
ATE204299T1 (de) † 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
DE4307508A1 (de) * 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
WO1995026403A1 (en) 1994-03-29 1995-10-05 Celltech Therapeutics Limited Antibodies against e-selectin
EP0813423B1 (en) * 1995-01-23 2002-07-03 Xenotech Incorporated Composition to inhibit osteolysis and metastasis
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20140212413A1 (en) * 1995-12-11 2014-07-31 New York University Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US7608262B2 (en) 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
EP0791360A3 (en) * 1996-02-29 1997-09-24 Bayer Corporation Treatment of septic shock with anti-TNF antibodies
EP2177517B1 (en) 1996-07-24 2011-10-26 Celgene Corporation Amino substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimide for reducing TNF alpha levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
WO2001036486A2 (en) 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
CA2292760A1 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
EP1032420A4 (en) * 1997-11-14 2004-09-15 Euro Celtique Sa IMMUNOGLOBULIN MOLECULES WITH SYNTHETIC VARIABLE REGION AND MODIFIED SPECIFICITY
AU771015B2 (en) * 1999-03-18 2004-03-11 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP2001299349A (ja) * 2000-04-19 2001-10-30 Suntory Ltd 新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU2001278980A1 (en) 2000-07-21 2002-02-05 Chugai Seiyaku Kabushiki Kaisha Coumarin derivatives useful as tnfalpha inhibitors
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
AU2003218432A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
ES2370710T3 (es) 2002-05-28 2011-12-22 Ucb Pharma, S.A. ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP1590431A4 (en) * 2003-01-08 2009-12-23 Applied Molecular Evolution ALPHA TUMOR NECROSIS FACTOR MOLECULES
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP2340850A1 (en) 2004-02-10 2011-07-06 The Regents of the University of Colorado, a Body Corporate Inhibition of factor B, the alternative complement pathway and methods related thereto
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
KR100971497B1 (ko) * 2004-12-29 2010-07-21 주식회사유한양행 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
CA3008270A1 (en) * 2005-09-21 2007-03-29 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
US7981414B2 (en) * 2005-12-20 2011-07-19 Cephalon Australia Pty Ltd Anti-inflammatory dAb
CN103232540A (zh) * 2006-02-01 2013-08-07 赛法隆澳大利亚控股有限公司 结构域抗体构建体
US7863426B2 (en) 2006-04-05 2011-01-04 Abbott Biotechnology Ltd. Antibody purification
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
KR101416078B1 (ko) * 2006-05-25 2014-07-07 글락소 그룹 리미티드 변형된 인간화 항­인터루킨­１８ 항체
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
BRPI0812398A2 (pt) 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US20100266604A1 (en) 2007-11-09 2010-10-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
CN102036683A (zh) * 2008-05-20 2011-04-27 株式会社钟化 细胞毒性组合物
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
BR112012025568A2 (pt) * 2010-04-07 2017-03-28 Abbvie Inc proteínas de ligação ao tnf-<244>.
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
CN105793439B (zh) * 2013-11-06 2020-09-04 阿斯图特医药公司 以生物样品进行的针对igfbp7的具有改进的性能的测定
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
GB201522394D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
SI3219726T1 (sl) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
EP3430044A1 (en) 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnf alpha -antibodies and functional fragments thereof
US10787508B2 (en) 2016-03-17 2020-09-29 Numab Innovation Ag Anti-TNFα-antibodies and functional fragments thereof
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
PT3219727T (pt) 2016-03-17 2021-01-21 Tillotts Pharma Ag Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
AU2017274442B2 (en) 2016-06-02 2021-08-19 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
CA3052095A1 (en) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
WO2019106609A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2019133827A1 (en) * 2017-12-29 2019-07-04 Board Of Regents, The University Of Texas System Antimicrobial nanobodies
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
KR20210122243A (ko) 2019-01-31 2021-10-08 누맙 세러퓨틱스 아게 ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
US12258393B2 (en) 2020-05-21 2025-03-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2022123293A1 (ko) 2020-12-09 2022-06-16 에이치케이이노엔 주식회사 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
WO2024200722A1 (en) 2023-03-28 2024-10-03 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
AU4182289A (en) * 1988-08-19 1990-03-23 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
EP1681305A3 (en) * 1991-03-18 2008-02-27 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
ATE204299T1 (de) * 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper

Also Published As

Publication number Publication date
JPH05507418A (ja) 1993-10-28
FI923737L (fi) 1992-08-20
CA2129554C (en) 1998-12-29
JP3145401B2 (ja) 2001-03-12
EP0927758A2 (en) 1999-07-07
GB2257145A (en) 1993-01-06
HU9202605D0 (en) 1992-10-28
NL9120013A (nl) 1992-11-02
PT99934A (pt) 1993-01-29
OA09666A (en) 1993-05-15
CA2076540A1 (en) 1992-06-22
NO923231D0 (no) 1992-08-18
NZ241147A (en) 1995-04-27
ES2190434T3 (es) 2003-08-01
EP0626389A1 (en) 1994-11-30
US20030199679A1 (en) 2003-10-23
HUT62661A (en) 1993-05-28
FI923737A0 (fi) 1992-08-20
NZ260226A (en) 1995-04-27
EP0626389B1 (en) 2002-12-04
GB9217880D0 (en) 1992-10-28
CA2076540C (en) 2001-03-27
JP3383795B2 (ja) 2003-03-04
CA2329482A1 (en) 1992-06-22
DE69117284D1 (de) 1996-03-28
BR9106232A (pt) 1993-03-30
GB9109645D0 (en) 1991-06-26
DK0516785T3 (da) 1996-03-18
NO20012882D0 (no) 2001-06-11
KR100253426B1 (ko) 2000-04-15
FI109800B (fi) 2002-10-15
CA2329482C (en) 2001-12-11
EP0516785B1 (en) 1996-02-21
EP0516785A1 (en) 1992-12-09
GR3019066T3 (en) 1996-05-31
CA2129554A1 (en) 1992-06-22
DE69133167T2 (de) 2003-07-24
AU657937B2 (en) 1995-03-30
JP2001114697A (ja) 2001-04-24
AU669083B2 (en) 1996-05-23
JPH10136986A (ja) 1998-05-26
DE69133167D1 (de) 2003-01-16
DE4193302C2 (de) 2000-08-24
ATE134387T1 (de) 1996-03-15
EP0927758A3 (en) 2001-02-21
PT99934B (pt) 1998-08-31
WO1992011383A1 (en) 1992-07-09
GB2257145B (en) 1995-06-14
DE69117284T2 (de) 1996-09-05
HU211626A9 (en) 1995-12-28
NO923231L (no) 1992-10-20
DE4193302T1 (de) 1993-02-18
DK0626389T3 (da) 2003-03-31
ATE228853T1 (de) 2002-12-15
AU7772394A (en) 1995-03-09
AU9108491A (en) 1992-07-22
NO20012882L (no) 1992-10-20

Similar Documents

Publication Publication Date Title
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
ATE153704T1 (de) Anti-t-zell rezeptordeterminanten zur behandlung von autoimmunkrankheiten
ATE240395T1 (de) Antikörper gegen e-selektin
ATE214943T1 (de) Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor
ES2082850T3 (es) Inmunoglobulinas preparadas geneticamente.
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DK0600930T3 (da) Diagnose og behandling af autoimmune sygdomme
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DE68925226D1 (de) Monoklonale Antikörper
DE69531290D1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
ATE120372T1 (de) Antikörper für die antilymphozyten- antikörpertherapie.
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE69522689D1 (de) Zellzyklus-unabhängige, gliomaoberflach-spezifische, menschliche monoklonale antikörper
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ES2061769T3 (es) Anticuerpo monoclonal y su utilizacion.
DK225689D0 (da) Anvendelse af metalloporphyriner til modvirkning af den toksiske virkning af tumorterapi
DE69221605D1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.
ATE180167T1 (de) Inhibition der ausscheidung von natrium durch die na-k-atpase

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 516785

Country of ref document: ES